We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Not a long term one to hold for growth but divi not too bad. I keep a few sentimental Wellcome plc shares (WF plc -> GW -> GSK). These shares hit around £20+ about 20 years ago just as I retired. So quite a lot of downward growth! BTW around the 90s both GW & AZN were approx both around £7 ce la vie.
...f could buy at this great low price instead of being a long term holder with other priorities in my p/f. For those readers who don't have this heavyweight creator of needed and exciting new drugs in their p/f, this is a great low price to satart adding. Please do a bit of homework and you could well agree/
Don't rule out foreign stakebuilding at this level.
....advises buy and hold underalued GSK, just as I did on a recent post. Stacks of value in their new drugs. If they don't move up soon, my view is still they will get takeover bids.
Price dipped some ,Also good to see more purchases showing . For the point of it ,might be interesting to look at bsfa share price today and in 3 and 6 months with the news expected .Want to see gsk price moving up more .
Https://www.gsk.com/en-gb/investors/dividend-and-share-price/dividend-calendar/
Is it ex dividend date today which would explain why it has dropped ?
Haven’t seen any news for this recent drop and every one else seems on the up!
As a retired litigation lawyer I am really comforted by the continued failure of litigants here against GSK.
Most if not all of these litigants will have been taken on 'no win no fee' and with a number of class actions now dismissed,
legal firms must be getting the wind up. Especially comforting was the last dismissal because it was by a Judge in Canada, not USA,
The sp does not reflect the way this cookie is crumbling. Without the Zantac litigation and with the number and extent of new FDA successes, my opinion is that GSK is far too cheap and at present a prime candidate for a takeover fight at £20 or more.
Paul Offit [ex FDA vaccines advisory committee member] gives his thoughts on GSK's RSV vaccine
https://pauloffit.substack.com/p/a-new-life-saving-vaccine-for-older
Good news & bad news from the article:
'The new RSV vaccine is a welcome addition in the fight against RSV. Now that it has been licensed by the FDA, it is likely that the CDC will recommend it for all adults over 60 at a meeting in June. Also, a similar RSV vaccine for older adults made by Pfizer will likely be considered by the FDA for licensure within a few weeks.'
But this is a big pie, so even if it is shared with Pfizerit could add tens of percent onto the annual free cash flow. First mover advantage could play into GSKs favour.
Sale of £804m worth of Haleon stock.
A positive court ruling from Canada relating to ranitidine.
Positive results in a phase III trial of its 5-in-1 meningococcal ABCWY vaccine candidate.
A very good day 😃
.
SaMason56 - Market is shot at present. This is now a posssible bid stock first and foremost but who knows when.
I am completely and utterly at a loss as to how GSK can gain approval for a first to market vaccine and it not have any impact on the share price. In fact since the news broke globally the share price has gone down.
This is huge news and a massive success…….No?
I give up
Another winner for us and now approved in the US too.
We need to make hay whilst we have the only fully approved vaccine for RSV.
https://www.cnbc.com/2023/05/03/rsv-vaccine-fda-approves-gsk-shot-for-older-adults.html?__source=androidappshare
...the weak pound since many of its sales will be for dollars and other currencies. Very undervalued.
gwm121,
GSK have used and continue to use artificial intelligence and machine learning to analyse vast sets of biological and genetic data that could help lead scientists to the next big breakthrough from bases in London, San Francisco and Philadelphia.
https://www.gsk.ai/
Astrazeneca are probably ahead of us in that they partnered with BenevolentAI several years ago as well as using machine learning for their R and D.
I think the BenevolentAI platform analyses all drugs and medicines looking for potential new applications for existing drugs/medicines.
https://www.benevolent.com/
When might they review that 3.9%?
Div yield is around 3.9% at the current shareprice.
100/1435 x 56p = 3.9%
fundementals shows divi as 6 percent. is that right.????????????
Will glaxo take full advantage of ai, data is money, there will be many questions answered from amagamating research scientific data from all the sources chat gpt has.
A fair reflection on yesterday's results.
https://www.hl.co.uk/feeds/apps/share-research?id=70844
Gwm - current annual dividend yield is c.56p I believe..the 5.9% is based on the dividend before the Haleon split.
You are quite right, i was being lazy and haven't calculated my yield based on my ave.purchase price.
I am in VOD too and am much less satisfied with my return there with a purchase price of about £1.75! Wouldn't touch it with a barge pole now but hope that it gets split up for a better sum of the parts than its paultry 96p today!!
I agree oldbutnotwisa,
68 medicines and vaccines in the piepline with 17 at the Phase III/registration stage bodes well for the future.
I'd rather see us progress that pipeline than be taken out for a bid at £17 to £18 in the near future.
Despite competition from Pfizer, Moderna and others I think our RSV vaccine will gain a decent share of the market based on its efficacy.
In the over 60's the vaccine was 82.6% effective in preventing lower respiratory tract disease and 94.1% effective against severe lower respiratory tract disease associated with an RSV infection.
I am 53 now, so I'll probably need it in the not too distant future!
At this price and with GSK's p[peline at present, I cannot believe we have not had at least one bid from anywhere.
Cheap as chips.